Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Histiocytic Disorders: early-phase trial registry

2 of 2 indexed Histiocytic Disorders trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Histiocytic Disorders: 2 US clinical trials tracked, 2 recruiting.

Histiocytic Disorders is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Center for International Blood and Marrow Transplant Research, running 1 of these trials.

Enrollment posture brief

Registry condition histiocytic-disorders

OPEN 2 | RECR 100% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Histiocytic Disorders (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Histiocytic Disorders

Histiocytic Disorders lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Histiocytic Disorders on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Histiocytic Disorders is recruiting above its size-band peers.

    2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Histiocytic Disorders records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) Drug
1 trials
Mirdametinib Drug
1 trials

US sites by state

Facility locations filed on Histiocytic Disorders trials. A trial with sites in several states counts in each.

Ohio 1 trials
Colorado 1 trials
California 1 trials
Arizona 1 trials
Arkansas 1 trials
Alabama 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Histiocytic Disorders page

2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Histiocytic Disorders condition card totals 2 registered trials; most-linked intervention A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs); top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.